1. Dreyling M, Ghielmini M, Rule S, et al. Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2021;32(3):298–308.
2. Roche. Lunsumio (mosunetuzumab): EU prescribing information; 2022. https://www.ema.europa.eu. Accessed 5 Jul 2022.
3. European Medicines Agency. Lunsumio; 2022. https://www.ema.europa.eu. Accessed 5 Jul 2022.
4. Roche. Product development portfolio; 2022. https://www.roche.com/solutions/pipeline. Accessed 5 Jul 2022.
5. Biogen. Biogen exercises option to participate in the development and commercialization of a late-stage bispecific antibody [media release]. 1 Feb 2022. https://investors.biogen.com.